Ascendis Pharma A/S said on
Monday the U.S. Food & Drug Administration had declined to
approve the Danish drugmaker s experimental therapy to treat
adult patients with a hormone disorder. | May 1, 2023
Operator: Good morning, and welcome to the Passage Bio Fourth Quarter and Full Year 2022 Financial Operating Results Conference Call. At this time, all participants are in listen-only mode.
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Vaishnavi, and I ll be your operator for today.